Navigation Links
EyeCare America Partners with National Eye Institute During May's Healthy Vision Month
Date:5/6/2009

National non-profit encourages scheduling an eye exam today!

San Francisco, CA (Vocus) May 6, 2009 -- EyeCare America honors Healthy Vision Month in May by encouraging people to get an eye exam during this national campaign, in partnership with the National Eye Institute. A recent study by the National Eye Institute found that more than 11 million Americans have common vision problems. While this number may sound alarming, the good news is that common vision problems can be detected through a comprehensive dilated eye exam and can often be corrected or treated.



Getting a comprehensive dilated eye exam is a painless procedure that can detect common vision problems and eye diseases, many of which have no early warning signs. Make sure your vision is the best it can be. Take action and call for an eye exam today. EyeCare America, the public service program of the Foundation of the American Academy of Ophthalmology, provides eye care to medically underserved individuals through a pool of over 7,000 volunteer ophthalmologists dedicated to serving their communities.

To see if you are eligible to be matched with a volunteer ophthalmologist, call EyeCare America's Seniors EyeCare Program 800-222-EYES (3937), helpline operates 24/7, year round. For more information, visit www.eyecareamerica.org.

Healthy vision can help keep you safe when you are driving behind the wheel, participating in sports, or taking part in recreational activities. It can also help to ensure that you maintain a healthy and active lifestyle well into your golden years.

Your eyes are an important part of your health. Take care of them so you can be confident you are seeing you
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Free Bilingual Eye Exam Guide Now Available to Eyecare Professionals
2. EyeCare America Offers No-Cost Medical Eye Care to Qualified Seniors In Support of National AMD Month - March 2009
3. During February's Valentine's Promotion EyeCare America Offers No-Cost Medical Eye Care to Qualified Seniors
4. This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?'
5. Prevention and Eyecare Begin at Home
6. EyeCare America Provides Free Dilated Eye Exams During Diabetes Awareness Month in November
7. EyeCare America Provides Free Dilated Eye Exams During Diabetes Awareness Month in November
8. National Non-Profit, EyeCare America, and the Maryland Society of Eye Physicians & Surgeons Host Finish Line Celebration for “EyeRide for Sight” Cyclists
9. EyeCare Americas EyeRide for Sight Cyclists Arrive in Washington, D.C.
10. Phyhealth Signs Agreement with Advantica EyeCare to Provide Vision Services for Pilot HMO
11. Contact lenses purchased over Internet may place individuals at risk for harmful eyecare practices
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EyeCare America Partners with National Eye Institute During May's Healthy Vision Month
EyeCare America Partners with National Eye Institute During May's Healthy Vision Month
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 1KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 2KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 3KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 4KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 5KV Pharmaceutical Divests ANDA for Generic Version of Duac 28R 29 57754 6Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 1Merrimack Pharmaceuticals Names Clet Niyikiza Ph D Senior Vice President Development 14175 2Alzheimers Soars Global Focus Needed 3A Study 57748 1Alzheimers Soars Global Focus Needed 3A Study 57748 2Alzheimers Soars Global Focus Needed 3A Study 57748 3
Other Medicine Technology:Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10